1-Cyclohexyl-2-methyl-1,2,3,4-tetrahydro-isoquinoline | 144757-93-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 1-Cyclohexyl-2-methyl-1,2,3,4-tetrahydro-isoquinoline
• 英文别名: 1-cyclohexyl-2-methyl-3,4-dihydro-1H-isoquinoline
• CAS: 144757-93-7
• 化学式: C₁₆H₂₃N
• 分子量: 229.365
• InChiKey: PHRHAKRBZMVQRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-甲基-1,2,3,4-四氢异喹啉 在 trityl tetrafluoroborate 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 反应 6.0h， 生成 1-Cyclohexyl-2-methyl-1,2,3,4-tetrahydro-isoquinoline
  参考文献：
  名称：

  De Costa; Radesca, Synthesis, 1992, # 9, p. 887 - 890

  摘要：

  DOI：

文献信息

• [EN] 6-HALO-PYRAZOLO[1, 5-A]PYRIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR (MGLUR) MODULATORS<br/>[FR] 6-HALO-PYRAZOLO[1,5-A]PYRIDINES, LEUR MÉTHODE DE PRÉPARATION ET LEUR UTILISATION COMME MODULATEURS DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE (MGLUR)
  申请人：MERZ PHARMA GMBH & CO KGAA

  公开号：WO2009095253A1

  公开（公告）日：2009-08-06

  The invention relates to 6-halo-pyrazolo[1, 5-a] pyridines of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.
• [EN] QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 DE LA QUINOLIZIDINE
  申请人：MERCK & CO INC

  公开号：WO2009117283A2

  公开（公告）日：2009-09-24

  The present invention is directed to compounds of formula (I) which are Ml receptor positive allosteric modulators and that are useful in the treatment of diseases in which the Ml receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the Ml receptor.